Inclusion Criteria:

          -  ≥18 years and ≤75 years in age

          -  Patients with relapsed or refractory AML

          -  No more than one prior stem cell transplant

          -  Has not received the chemotherapy regimen to be used for induction on this trial

          -  Is considered medically eligible to receive the chemotherapy regimen to be used for
             induction on this trial

        Exclusion Criteria:

          -  Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage
             (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or
             secondary refractory AML.

          -  Active signs or symptoms of CNS involvement by malignancy.

          -  Stem cell transplantation ≤4 months prior to dosing.

          -  Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other
             experimental therapy or chemotherapy within 14 days of dosing.

          -  Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.

          -  Inadequate organ function.

          -  Abnormal liver function.

          -  Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.

          -  Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).

          -  Uncontrolled acute life-threatening bacterial, viral, or fungal infection.

          -  Clinically significant cardiovascular disease.

          -  Major surgery within 4 weeks of dosing.